Interventions for hypertension and stroke

First-in-human results of the Omega left atrial appendage occluder for patients with non-valvular atrial fibrillation

EuroIntervention 2021;17:376-379. DOI: 10.4244/EIJ-D-20-00552

Ben Wilkins
Ben Wilkins1, MBChB; Suphot Srimahachota2, MD; Ole De Backer3, MD, PhD; Smonporn Boonyartavej2, MD; Vorarit Lertsuwunseri2, MD; Monravee Tumkosit4, MD; Lars Søndergaard3, MD, DMSc
1. Department of Cardiology, Dunedin Hospital, Dunedin, New Zealand; 2. Cardiac Center and Division of Cardiovascular Disease, Department of Medicine, King Chulalongkorn Memorial Hospital and Chulalongkorn University, Bangkok, Thailand; 3. The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 4. Cardiac Center and Department of Radiology, King Chulalongkorn Memorial Hospital and Chulalongkorn University, Bangkok, Thailand

Several strategies have been devised to obliterate the left atrial appendage (LAA) space, which is the suspected origin of the majority of cardioembolic thrombi in patients with non-valvular atrial fibrillation (NVAF)-related stroke1. The Omega™ LAA occluder (Vascular Innovations Co., Ltd., Nonthaburi, Thailand) is a novel self-expanding, cup-and-disc device made from a continuous, platinum-coated nitinol wire mesh (Figure 1), designed to occlude the LAA. The cup and disc are linked together by a flexible connecting waist. The disc has a polypropylene fabric securely sewn inside it, adding to the occlusive aspect of the device. For stabilisation, the cup ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Interventions for valvular diseaseInterventions for strokeOther valvular and structural interventionsLAA closure
Read next article
Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries

Latest news